You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》吉利德(GILD.US)季度少賺31% 愛滋病藥及新冠藥銷售勝預期
阿思達克 10-28 11:25
新冠藥瑞德西韋生產商吉利德(Gilead)(GILD.US)公佈第三季業績。季度純利17.89億美元,按年跌31%,每股季度攤薄純利1.42美元,經調整後爲1.9美元,高於市場預期的1.43美元。季度收入70.42億美元,按年跌5%,高於市場預期的61.2億美元。 瑞德西韋季內銷售按年跌52%至9.25億美元,高於市場預期的3.28億美元。公司研發的另一新冠口服藥料於未來數月進入第三階段臨牀測試。另外,公司的愛滋病藥物季度銷售按年升7%至44.87億美元,癌症藥拓達維(Trodelvy)銷售按年升78%至1.8億美元,細胞療法藥物銷售按年升79%至3.98億美元。 公司上調全年銷售預測,由介乎245億至250億美元上調至介乎259億至262億美元,全年經調整每股盈利預測亦由介乎2.9至3.3美元上調至介乎3.35至3.55美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account